Close
Smartlab Europe
Inizio Ignite

Press Releases

HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

HighTide Therapeutics, Inc., a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program. The agreement will...

Velocity Clinical Research acquires Meridian Clinical Research creating largest global research sites busines

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in...

Pfizer and BioNTech Receive U.S. FDA EUA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Pfizer Inc. and BioNTech SE announced the U.S. FDA granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of...

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

AbbVie and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases,  announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage...

CluePoints Appoints Andy Cooper as New Chief Executive Officer

RBQM leader, CluePoints, has announced Andy Cooper has been appointed as its new Chief Executive Officer. Cooper succeeds Co-Founder, Francois Torche, who is stepping back as CEO to focus his full attention on the strategic direction of CluePoints’ world-leading...

PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations

PHASTAR, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. In...

Inizio acquires Evolution Road, bolstering Evoke’s digital innovation and omnichannel offering

Inizio, a strategic partner for companies in health and life sciences, has today announced the acquisition of Evolution Road, a digital innovation company in life science omnichannel, digital marketing and digital health strategy. Evolution Road will become part of Inizio’s...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »